c-Met and PDGFR signaling pathways are known to promote GBM cell proliferation and motility [24, 25] and therefore, it is conceivable that reduction of c-Met and PDGFR activity by FRMD6 leads to the reduced GBM cell proliferation/invasiveness and GBM growth/progression. The gene discussed is MET; the disease is glioblastoma.